4-Dimethylaminoazobenzenes: carcinogenicities and reductive cleavage by microsomal azo reductase.
Twenty-four 4-dimethylaminoazobenzenes (DABs) in which systematic structural modifications have been made in the prime ring have been studied for substrate specificity for microsomal azo reductase. The DABs were also evaluated for carcinogenicity and it was found that there was no correlation between carcinogenicity and extent of azo bond cleavage by azo reductase. While any substituent in the prime ring reduces the rate of cleavage of the azo bond relative to the unsubstituted dye, there is a correlation between substituent size and susceptibility to the enzyme. Substituent size was also found to be a significant factor in the induction of hepatomas by the dyes. Preliminary studies have shown that there appears to be a positive correlation between microsomal riboflavin content and the activity of the azo reductase.
D000818:Animals; D055598:Chemical Phenomena; D002621:Chemistry; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced*; D008862:Microsomes, Liver / Q000201:enzymology*; D009152:Mutagenicity Tests; D009247:NADH, NADPH Oxidoreductases / Q000378:metabolism*; D009601:Nitroreductases; D010084:Oxidation-Reduction; D051381:Rats; D011919:Rats, Inbred Strains; D012256:Riboflavin / Q000037:antagonists & inhibitors / Q000378:metabolism; D013329:Structure-Activity Relationship; D013379:Substrate Specificity; D004124:p-Dimethylaminoazobenzene / Q000378:metabolism / Q000494:pharmacology*
D004124:p-Dimethylaminoazobenzene; D009247:NADH, NADPH Oxidoreductases; D009601:Nitroreductases; C021106:azoreductase; D012256:Riboflavin